R. McMenemin

2.2k total citations · 1 hit paper
42 papers, 1.2k citations indexed

About

R. McMenemin is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, R. McMenemin has authored 42 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 15 papers in Surgery and 13 papers in Oncology. Recurrent topics in R. McMenemin's work include Prostate Cancer Treatment and Research (10 papers), Bladder and Urothelial Cancer Treatments (8 papers) and Lung Cancer Research Studies (7 papers). R. McMenemin is often cited by papers focused on Prostate Cancer Treatment and Research (10 papers), Bladder and Urothelial Cancer Treatments (8 papers) and Lung Cancer Research Studies (7 papers). R. McMenemin collaborates with scholars based in United Kingdom, Canada and Ireland. R. McMenemin's co-authors include N. O’Rourke, M. Snee, Janusz Jankowski, K. G. Wormsley, Corinne Faivre‐Finn, Susan Harden, N. Mohammed, Jan P. van Meerbeeck, P. Fournel and Adityanarayan Bhatnagar and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Gut.

In The Last Decade

R. McMenemin

40 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

2017 354 citations Corinne Faivre‐Finn, M. Snee et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by R. McMenemin

Since Specialization

Citations

This map shows the geographic impact of R. McMenemin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. McMenemin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. McMenemin more than expected).

Fields of papers citing papers by R. McMenemin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. McMenemin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. McMenemin. The network helps show where R. McMenemin may publish in the future.

Co-authorship network of co-authors of R. McMenemin

This figure shows the co-authorship network connecting the top 25 collaborators of R. McMenemin. A scholar is included among the top collaborators of R. McMenemin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. McMenemin. R. McMenemin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Quality-of-life outcomes in metastatic spinal cord compression: findings from the SCORAD trial 2024 ·JNCI Journal of the National Cancer Institute ·Peter Hoskin, Krystyna Reczko, (unknown), Allan Hackshaw, Andre Lopes, (unknown), Kirsten Hopkins, Vivek Misra, Tanya Holt, R. McMenemin, Fiona McKinna, (unknown), Andrew Bates, N. O’Rourke, J.F. Lester, (unknown), Daphne Roos, Guy J. Brown, (unknown), Sharon Forsyth	2
2	Prognostic factors for survival and ambulatory status at 8 weeks with metastatic spinal cord compression in the SCORAD randomised trial 2022 ·Radiotherapy and Oncology ·Peter Hoskin, Kirsten Hopkins, Vivek Misra, Tanya Holt, R. McMenemin, Fiona McKinna, Krishnaswamy Madhavan, Andrew Bates, N. O’Rourke, J.F. Lester, (unknown), Daniel Roos, (unknown), (unknown), Sharon Forsyth, Krystyna Reczko, Allan Hackshaw, Catherine O’Hara, Andre Lopes	5
3	Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer –5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life 2020 ·Clinical Oncology ·Xue Jiang, (unknown), R. Pearson, Darren Leaning, (unknown), Alexander Burns, Ashraf Azzabi, J. Frew, R. McMenemin, Ian Pedley	13
4	Sequential chemotherapy followed by radical thoracic radiotherapy (50 Gy in 25 fractions) in limited stage small cell lung cancer 2020 ·ecancermedicalscience ·Muhammad Shahid Iqbal, (unknown), Fiona McDonald, Philip J. Atherton, Helen Turnbull, (unknown), (unknown), P. Mulvenna, Josef Kovařík, R. McMenemin, J. Gardiner, Alastair Greystoke	0
5	18F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial 2019 ·Journal of Thoracic Oncology ·Prakash Manoharan, Ahmed Salem, Hitesh Mistry, (unknown), Susan Harden, P. J. Julyan, Imogen Locke, J. McAleese, R. McMenemin, N. Mohammed, M. Snee, (unknown), (unknown), Corinne Faivre‐Finn	20
6	OA13.01 The Impact of [18F]fludeoxyglucose PET/CT in Small-Cell Lung Cancer: Analysis of the Phase 3 CONVERT Trial 2018 ·Journal of Thoracic Oncology ·(unknown), Ahmed Salem, Hitesh Mistry, (unknown), Susan Harden, P. J. Julyan, Imogen Locke, J. McAleese, R. McMenemin, N. Mohammed, M. Snee, (unknown), Susan L. Woods, Corinne Faivre‐Finn	1
7	Hypofractionated Concomitant Chemoradiation in Inoperable Locally Advanced Non-small Cell Lung Cancer: A Report on 100 Patients and a Systematic Review 2018 ·Clinical Oncology ·Muhammad Shahid Iqbal, (unknown), R. McMenemin, Philip J. Atherton, Fiona McDonald, (unknown), (unknown), Josef Kovařík, Helen Turnbull, Leslie G. Dodd, P. Mulvenna, Alastair Greystoke	14
8	VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland 2017 ·International Journal of Oncology ·Syed A. Hussain, Jawaher Ansari, Robert Huddart, Derek G. Power, J. Lyons, James Wylie, (unknown), Nils Elander, R. McMenemin, Lisa Pickering, Guy Faust, (unknown), Richard Jackson	6
9	Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial breakdown → 2017 ·The Lancet Oncology ·Corinne Faivre‐Finn, M. Snee, Linda Ashcroft, W. Appel, Fabrice Barlési, Adityanarayan Bhatnagar, Andrea Bezjak, Felipe Cardenal, P. Fournel, Susan Harden, C. Le Péchoux, R. McMenemin, N. Mohammed, Mary O’Brien, Jason Pantarotto, Veerle Surmont, Jan P. van Meerbeeck, Penella J. Woll, Paul Lorigan, Fiona Blackhall	354
10	An update on clinical outcome data for a phase II randomized study comparing androgen deprivation therapy plus docetaxel versus androgen deprivation therapy alone in men with locally advanced/metastatic hormone sensitive prostate cancer. 2017 ·Journal of Clinical Oncology ·(unknown), J. Frew, R. McMenemin, Ashraf Azzabi, Ian Pedley	1
11	Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non–castration-resistant prostate cancer 2015 ·Urologic Oncology Seminars and Original Investigations ·Prabhakar Rajan, J. Frew, James M. Wilson, Ashraf Azzabi, R. McMenemin, Jacqueline Stockley, Naeem Soomro, Garrett Durkan, Ian Pedley, Hing Y. Leung	4
12	Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer 2014 ·BMC Cancer ·Prabhakar Rajan, Jacqueline Stockley, Ian Sudbery, Janis Fleming, Ann Hedley, Gabriela Kalna, David Sims, Chris P. Ponting, Andreas Heger, Craig Robson, R. McMenemin, Ian Pedley, Hing Y. Leung	39
13	SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status 2014 ·European Journal of Cancer ·J. Maguire, Iftekhar Khan, R. McMenemin, N. O’Rourke, S.G. McNee, V. Kelly, C. Peedell, M. Snee	94
14	Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy 2013 ·European Urology ·Prabhakar Rajan, Ian Sudbery, (unknown), Ernest Mui, Janis Fleming, (unknown), Imran Ahmad, Joanne Edwards, Owen J. Sansom, David Sims, Chris P. Ponting, Andreas Heger, R. McMenemin, Ian Pedley, Hing Y. Leung	114
15	Chemotherapy for bladder cancer: an update 2012 ·Trends in Urology & Men s Health ·Heather Payne, R. McMenemin, James Green, Benjamin W. Lamb, (unknown), Jawaher Ansari, (unknown)	1
16	The Implementation of an Advanced Treatment Planning Algorithm in the Treatment of Lung Cancer with Conventional Radiotherapy 2009 ·Clinical Oncology ·(unknown), Philip J. Atherton, R. McMenemin, Fiona McDonald, (unknown), (unknown), (unknown)	8
17	P-419 A randomised controlled trial of radiotherapy to mesotheliomadrain sites 2005 ·Lung Cancer ·N. O’Rourke, Jordi Curto, R. McMenemin, J. Hill, (unknown)	3
18	Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I 2002 ·European Journal of Nuclear Medicine and Molecular Imaging ·Thomas E. Hilditch, Mary F. Dempsey, (unknown), R. McMenemin, Nicholas Reed	83
19	A Phase II Study of CaelyxTM (Liposomal Doxorubicin) in Metastatic Carcinoma of the Prostate: Tolerability and Efficacy Modification by Liposomal Encapsulation 2002 ·Investigational New Drugs ·R. McMenemin, Graham Macdonald, Leslie Moffat, Donald Bissett	19
20	Proliferating cell nuclear antigen in oesophageal diseases; correlation with transforming growth factor alpha expression. 1992 ·Gut ·Janusz Jankowski, R. McMenemin, C. C.‐W. Yu, David A. Hopwood, K. G. Wormsley	58

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact